Part D Pricing and Subpoena Power: What the November Elections Could Mean for Wall Street
This article was originally published in RPM Report
Executive Summary
The pharmaceutical industry has a lot riding on the mid-term elections: the Democrats only need to take back one chamber of Congress to do damage on Wall Street.
You may also be interested in...
Preparing for Health Care Reform: Why Big Pharma Thinks it Can Avoid Another "Hillarycare"
Should a Democrat take the White House next January, top pharmaceutical executives expect a serious push for health care reform. The prospect of a health care reform debate triggers the specter of a single-payor, government-run system with price controls. But Democrats are singing a surprisingly soothing tune.
Tilting the Contracting Scales: Part D Plans Have Advantages Over Manufacturers in 2008
Contracting between pharma companies and Part D plan sponsors that took place last year for 2007 pricing and formulary placement was a relatively straightforward process. This year will be more interesting.
Message From Wall Street: Cap Those Price Increases
With the Democrats in control of Congress and high drug prices still making headlines, some Wall Street analysts are suggesting a proactive, and surprising, response from Big Pharma: voluntary price caps.